Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

2.81
-0.11 (-3.77%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :94,493
Date :03-18-2024

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

9月 21st, 2023|Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company已关闭评论

18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase [...]

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

8月 2nd, 2023|Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally已关闭评论

JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to [...]

Oramed to Present at the 83rd American Diabetes Association Conference

6月 20th, 2023|Oramed to Present at the 83rd American Diabetes Association Conference已关闭评论

NEW YORK, June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83rd Scientific [...]

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

5月 18th, 2023|Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit已关闭评论

NEW YORK, May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type [...]